The impact of diabetes‐related complications on healthcare costs: new results from the UKPDS (UKPDS 84)

To estimate the immediate and long‐term inpatient and non‐inpatient costs for Type 2 diabetes‐related complications.

[1]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[2]  A. Basu,et al.  Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. , 2005, Biostatistics.

[3]  M. Petticrew.  Diagoras of Melos (500 BC): an early analyst of publication bias , 1998, The Lancet.

[4]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[5]  C. Morris,et al.  A Comparison of Alternative Models for the Demand for Medical Care , 1983 .

[6]  A. Basu.  Extended Generalized Linear Models: Simultaneous Estimation of Flexible Link and Variance Functions , 2005 .

[7]  J. Salomon,et al.  Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis , 2010, PLoS medicine.

[8]  C. Kelman,et al.  Estimating the cost of complications of diabetes in Australia using administrative health-care data. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[10]  U. Gerdtham,et al.  Estimating the Cost of Diabetes Mellitus-Related Events from Inpatient Admissions in Sweden Using Administrative Hospitalization Data , 2012, PharmacoEconomics.

[11]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[12]  John R. Williams.  DECLARATION OF HELSINKI , 1964 .

[13]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[14]  R Legood,et al.  The impact of diabetes‐related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65) , 2003, Diabetic medicine : a journal of the British Diabetic Association.